Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
HYPOTHESIS: The administration of vitamin D supplements to patients who have a positive
diagnosis for SARS-Cov-2, acute pneumonia requiring hospital admission and vitamin D
deficiency have a more favourable evolution than subjects not treated with vitamin D
(placebo). This favourable evolution will translate into a reduction in mortality, fewer ICU
admissions and fewer days of stay in hospital.
OBJECTIVES:
PRINCIPAL: To assess whether the group of patients receiving vitamin D supplements have a
less severe evolution of their acute pneumonia, translated into lower mortality, than
patients who do not receive that supplement.
SECONDARY: 1) To determine the number of intensive care admissions and the number of days of
admission in both groups (control group and intervention group). 2) To estimate the
prevalence of Vitamin D deficiency in the patients studied and the effectiveness of its
supplementation. 3) To establish the degree of complexity of each study group and carry out a
cost-effectiveness study.
METHODOLOGY: DESIGN: Clinical trial, randomized, placebo-controlled and double-blind, with
two parallel groups The active treatment will be vitamin D (Hydroferol soft capsules of 0.266
mg). The placebo will consist of a tablet with the same external characteristics and with the
same treatment scheme but which will not contain any vitamin D active ingredients.